Cargando…

Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis

Non-alcoholic fatty liver disease (NAFLD) refers to fatty infiltration of liver in the absence of significant alcohol intake, use of steatogenic medication, or hereditary disorders. It is a common cause of chronic liver disease with a worldwide estimated prevalence ranging from 6.3% to 33%. The NAFL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sao, Rahul, Aronow, Wilbert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	State of the Art Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209727/ https://www.ncbi.nlm.nih.gov/pubmed/30393477 http://dx.doi.org/10.5114/aoms.2017.68821

Ejemplares similares

Obstructive sleep apnoea and cardiovascular disease: a literature review
por: Assallum, Hussein, et al.
Publicado: (2019)

Peripheral arterial disease of the lower extremities
por: Aronow, Wilbert S.
Publicado: (2012)

Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update
por: Miranda, Cesare, et al.
Publicado: (2023)

Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease
por: Thibaut, Ronan, et al.
Publicado: (2021)

Lipid-lowering therapy in older persons
por: Aronow, Wilbert S.
Publicado: (2015)

Management of cardiac hemochromatosis
por: Aronow, Wilbert S.
Publicado: (2017)

Update of treatment of heart failure with reduction of left ventricular ejection fraction
por: Aronow, Wilbert S.
Publicado: (2016)

Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
por: Mitrovic, Bojan, et al.
Publicado: (2022)

Reversal agents of non-vitamin K dependent anticoagulants: a rapid review of the changing horizon
por: Kaur, Supreet, et al.
Publicado: (2016)

Therapeutic options for severe asthma
por: Mathew, Jilcy, et al.
Publicado: (2012)

Lung cancer screening: history, current perspectives, and future directions
por: Sharma, Divakar, et al.
Publicado: (2015)

Managing Hypertension in the elderly: What’s new?
por: Aronow, Wilbert S.
Publicado: (2020)

Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
por: Piña, Pamela, et al.
Publicado: (2022)

The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Management of massive and nonmassive pulmonary embolism
por: Sekhri, Vishal, et al.
Publicado: (2012)

Sarcopenia and Cardiovascular Diseases
por: Damluji, Abdulla A., et al.
Publicado: (2023)

Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy
por: Patail, Haris, et al.
Publicado: (2023)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

On the present and future role of Lp-PLA(2) in atherosclerosis-related cardiovascular risk prediction and management
por: Fras, Zlatko, et al.
Publicado: (2020)

COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases
por: Zhang, Yuanyuan, et al.
Publicado: (2021)

Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease
por: Sharma, Niketa, et al.
Publicado: (2023)

Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases: Roadmap to the Clinic
por: Sahoo, Susmita, et al.
Publicado: (2021)

Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
por: Salah, Husam M., et al.
Publicado: (2021)

Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects
por: Cicero, Arrigo F.G, et al.
Publicado: (2012)

Exercise and Coronary Atherosclerosis: Observations, Explanations, Relevance, and Clinical Management
por: Aengevaeren, Vincent L., et al.
Publicado: (2020)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Small non-coding RNA therapeutics for cardiovascular disease
por: Shah, Ajay M, et al.
Publicado: (2022)

Determining Subclinical Cardiovascular and Cardiac Diseases in Patients with Non-Alcoholic Fatty Liver Disease
por: Karaoğlan, Beliz Bahar, et al.
Publicado: (2023)

Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review
por: Watanabe, Jun, et al.
Publicado: (2020)

Depression and cardiovascular comorbidity
por: Glassman, Alexander H.
Publicado: (2007)

Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
por: Fadaei, Reza, et al.
Publicado: (2018)

Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease
por: Karami, Sara, et al.
Publicado: (2021)

Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis
por: Hsiao, Chia-Chi, et al.
Publicado: (2021)

Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions
por: Ertek, Sibel, et al.
Publicado: (2012)

Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3
por: Hogas, Simona, et al.
Publicado: (2016)

GlycA measured by NMR spectroscopy is associated with disease activity and cardiovascular disease risk in chronic inflammatory diseases()
por: Mehta, Nehal N., et al.
Publicado: (2020)

Targeting the Inflammasome in Cardiovascular Disease
por: Olsen, Maria Belland, et al.
Publicado: (2021)

Iron deficiency and cardiovascular disease
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Immunometabolism at the Heart of Cardiovascular Disease
por: DeBerge, Matthew, et al.
Publicado: (2023)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
por: Banach, Maciej, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qfcntgp42lsq8ics6t0jde1orq